Premium
ME‐401, A NOVEL, ORAL, POTENT AND SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3‐KINASE P110δ (PI3Kδ) IN EARLY CLINICAL DEVELOPMENT FOR B‐CELL LYMPHOID MALIGNANCIES
Author(s) -
Ghalie R.G.,
Pagel J.M.,
Soumerai J.,
Iasonos A.,
Patel K.,
Moreno O.,
Butler T.,
Zelenetz A.D.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2439_184
Subject(s) - medicine , chronic lymphocytic leukemia , pharmacokinetics , pharmacodynamics , ex vivo , pharmacology , refractory (planetary science) , leukemia , oncology , in vivo , biology , microbiology and biotechnology , astrobiology